Epigral manufactures essential industrial chemicals including caustic soda and chlorine derivatives like CPVC resin and epichlorohydrin, which are used in construction, water treatment, and pharmaceuticals.
The company possesses a cost-scale advantage through a highly integrated manufacturing complex where byproducts like chlorine and hydrogen are used as feedstocks for higher-value specialty chemicals. This integration is corroborated by durable ROCE exceeding 20% and a high degree of captive raw material consumption.
Management has consistently reinvested earnings into high-return downstream integration projects, successfully transitioning the revenue mix from 25% to 54% specialty chemicals over four years while maintaining a conservative debt-to-equity ratio.
The downfall began when the massive capital work-in-progress failed to yield the expected returns, as global glycerin and PVC price collapses turned the integrated feedstock advantage into a liability. The related party transactions with Meghmani Organics, previously dismissed as routine, became a conduit for siphoning capital as the parent entity faced its own liquidity crisis. As margins compressed under the weight of high fixed costs and volatile commodity inputs, the interest coverage ratio evaporated, and the once-clean earnings were revealed to be propped up by aggressive mark-to-market accounting on derivative swaps that eventually turned toxic.
RichFakir rates Epigral Ltd's business quality as wonderful — 71/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Epigral Ltd is trading about 36% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Epigral Ltd is: Buy candidate. A wonderful business trading below what we think it is worth — so it makes our buy list.
RichFakir's educational estimate of Epigral Ltd's fair value is about ₹1,364 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →